Cubist to investigate novel GPCR target for acute care with Heptares
This article was originally published in Scrip
Executive Summary
Cubist Pharmaceuticals has tapped Heptares Therapeutics, the UK-based GPCR specialist, to help it develop new medicines for an acute care indication.